Catalyst Wire Dossier Catalyst Wire Dossier

Libmyris

adalimumab · Stada Arzneimittel AG
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Libmyris, covering 2026-03-19 to 2026-07-13. Get the full timeline:

Most recent: EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG

See pricing